IMIC(SZ:000516)2020-10-28 16:00Financial Performance - Operating revenue for the reporting period was CNY 432,275,315.05, representing an increase of 88.59% year-on-year[3]. - Net profit attributable to shareholders was CNY -154,358,415.78, a decrease of 509.97% compared to the same period last year[3]. - Basic earnings per share were CNY -0.080, a decrease of 515.38% compared to the same period last year[3]. - The weighted average return on net assets was -3.41%, a decrease of 2.94% compared to the previous year[3]. - Operating revenue increased by 59.41% year-on-year, primarily driven by increased medical income from the Xi'an International Medical Center[9]. - Operating costs increased by 135.09% year-on-year, mainly due to increased medical costs following the operational commencement of the Xi'an International Medical Center[9]. - The company reported a significant decrease in employee compensation payable, which fell to CNY 71,434,527.18 from CNY 136,948,615.93, a reduction of about 47.92%[24]. - The net profit for Q3 2020 was -506,276,161.23 CNY, compared to -25,288,245.88 CNY in the same period last year, indicating a significant decline[39]. - The total comprehensive income for the third quarter was CNY -156,648,077.41, compared to CNY -27,422,178.03 in the same period last year[33]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 10,652,081,796.92, an increase of 6.19% compared to the end of the previous year[3]. - The total liabilities rose to CNY 6,159,764,082.91 from CNY 5,034,979,331.06, reflecting an increase of around 22.36%[24]. - The company's non-current assets totaled CNY 9,015,469,065.91, up from CNY 8,410,602,746.58, indicating a growth of about 7.19%[23]. - The company's total liabilities amounted to CNY 627,511,972.17, compared to CNY 405,095,708.11 at the end of 2019[29]. - Total liabilities reached CNY 5,034,979,331.06, with current liabilities at CNY 1,865,913,254.19 and non-current liabilities at CNY 3,169,066,076.87[54]. - The company has a long-term loan of CNY 48,000,000.00 and other non-current liabilities totaling CNY 57,783,433.17[56]. Cash Flow - The net cash flow from operating activities was CNY 86,723,404.54, an increase of 271.47% year-on-year[3]. - Cash and cash equivalents decreased by 36.13% compared to the beginning of the year, primarily due to increased cash payments for investments during the reporting period[9]. - Operating cash flow for Q3 2020 was negative at -173,335,487.51 CNY, compared to a positive 77,316,381.17 CNY in Q3 2019, indicating a significant decline in operational performance[46]. - The company's cash and cash equivalents at the end of Q3 2020 were 617,557,243.68 CNY, down from 1,339,874,701.94 CNY at the end of Q3 2019, reflecting liquidity challenges[47]. - The total cash inflow from investment activities was 1,051,616,542.71 CNY, down from 2,195,373,561.98 CNY in the same period last year, reflecting reduced investment recovery[47]. Shareholder Information - The total number of shareholders at the end of the reporting period was 68,393[6]. - The largest shareholder, Shaanxi Century New Yuan Commercial Management Co., Ltd., held 18.88% of the shares[6]. - The company plans to issue up to 304,878,048 shares to its controlling shareholder, raising a total of up to 100 million yuan for working capital and bank loan repayment[11]. Strategic Initiatives - There were no significant changes in the company's strategy or new product developments mentioned during the call[5]. - A strategic cooperation agreement was signed with Shaanxi University of Traditional Chinese Medicine to enhance collaboration in medical education and research[11]. - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[25]. Investment and Expenses - The company reported non-recurring gains and losses totaling CNY 10,406,697.38 for the reporting period[4]. - The company's investment income decreased by 90.34% year-on-year, mainly due to lower returns from entrusted financial investments compared to the previous period[9]. - The company reported R&D expenses of CNY 2,172,521.37 for Q3 2020, up from CNY 1,760,287.96 in the previous year[31]. - The company incurred management expenses of 25,767,558.13 CNY, down from 32,527,926.59 CNY in the previous year[43].